Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee
- With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee.
- MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief.
Aachen, Germany, 12 April 2021 –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and functional improvements compared to placebo (saline injection), as well as a favourable safety profile.
“Osteoarthritis is a progressive condition that currently cannot be cured.The inflamed, swollen and painful joints lead to limitation on mobility of the affected patients and may impact their quality of life significantly. Millions of patients currently receive intra-articular corticosteroids or need to undergo knee replacement surgery as last remaining treatment option,” says Jan Adams, MD, Chief Scientific Officer Grünenthal. “With MTX-071, we aim to provide these patients with a well tolerable, non-opioid therapy option that provides long-lasting pain relief and functional improvement of the affected joints.”
Grünenthal is currently preparing two pivotal Phase III studies to investigate the efficacy, safety and tolerability of MTX-071 in patients with pain associated with osteoarthritis of the knee. The studies will start in 2021 and they are part of a global development programme aimed at meeting the requirements for approval in the EU, the US, Japan and China. The mechanism of action is well validated by clinical studies with other TRPV1 agonists.
“Through the acquisition of Mestex, Grünenthal is well positioned to tap into the global osteoarthritis market. Over 50 million people are affected by osteoarthritis of the knee across the US and the EU.” says Gabriel Baertschi, Chief Executive Officer Grünenthal. “We are confident in the mechanism of action of MTX-071 and will explore its potential for the treatment of osteoarthritis related pain in additional joints.”
This acquisition will further strengthen Grünenthal’s pain-focused late-stage pipeline. The company recently announced a Phase III trial that studies the efficacy, safety and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) with the goal of expanding the current US label.
MTX-071 is an intra-articular injection of resiniferatoxin for the treatment of pain in patients with advanced knee osteoarthritis. Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. The investigational medicine is currently concluding Phase II and about to enter Phase III. Data shows a long-lasting and significant analgesic effect and functional improvements compared to placebo (saline injection), as well as a favourable safety profile.
Osteoarthritis (OA) can be defined as a group of distinct, but overlapping diseases. They may have different etiologies, but similar biological, morphological, and clinical outcomes that affect the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in people aged 65 and over. Its etiology is not fully understood, although there are several related factors including female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.
Osteoarthritis is a joint disease in which the tissues in the joint break down over time. Common symptoms of osteoarthritis include joint pain, stiffness and swelling, as well as changes in how the joint moves and feeling like the joint is loose or unstable. The most commonly affected joints include the hands, knees, hips, neck and lower back. Treatment of osteoarthritis usually includes exercises, maintaining a healthy weight, wearing braces to help with stability, and taking medication, if prescribed. Many patients will require joint replacement surgery.
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
National Institute of Arthritis and Musculoskeletal and Skin Diseases; What Causes Osteoarthritis, Symptoms & More | NIAMS (nih.gov)
Follow us on:
LinkedIn: Grunenthal Group
Fabia Kehren, Head External Communications & Editorial Management
Phone: +49 241 569-3269
Florian Dieckmann, Head Global Communications
Phone: +49 241 569-2555
About Grünenthal Group
Subscribe to releases from Grünenthal Group
Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Grünenthal Group
Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis29.3.2022 12:05:00 CEST | Pressmeddelande
Aachen, Germany and Raleigh, North Carolina
Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine7.3.2022 13:11:29 CET | Pressmeddelande
Aachen, Germany, 7 March 2022 –Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital of RWTH Aachen to provide urgently needed pain medication to the region. The first transport with medicine is set to leave Aachen this week. “We are shocked and saddened by the attack on Ukraine. Our full solidarity is with Ukraine’s people and everyone affected, no matter where they come from. Grünenthal will contribute to ensuring urgently needed medical care”, said Gabriel Baertschi, CEO of Grünenthal. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to c
First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist 29.9.2021 10:55:16 CEST | Press release
Aachen, Germany, 29 September 2021 –Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its peripherally restricted Nociceptin/Orphanin FQ peptide receptor (NOP) agonist. The compound is being developed to provide a non-opioid therapy option that offers a strong analgesic effect without the side effects commonly associated with opioids. The Experimental Medicine Trial will evaluate the extent and duration of the pharmacological effect of the oral NOP agonist in an experimental pain model. The results of the trial are expected to be available in early 2022. The trial explores how the NOP agonist influences pain signalling and perception using laser evoked potentials (LEPs) in an experimental pain model with 30 healthy participants. On five different occasions, the participants will receive either the NOP agonist or pregabalin or placebo. The trial explores three different doses of the NOP agonist;
First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain 10.8.2021 09:00:00 CEST | Press release
The study AV001 aims to include the treatment of post-surgical neuropathic pain (PSNP) in the U.S. label. QUTENZA® is currently approved for use in adults in the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. Post-surgical neuropathic pain is a debilitating complication of surgery that affects approximately 13% of all patients who undergo surgery, representing 3.3 million patients per year in the US. Aachen, Germany, & Morristown, N.J., 10 August 2021 –Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label. The trial will include over 400 patients who suffer from moderate
Grünenthal’s Glucocorticoid Receptor Modulator enters clinical development27.7.2021 10:50:36 CEST | Press release
Aachen, Germany, 27 July 2021 –Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile compared to current glucocorticoid-based therapies like prednisolone. The Phase I trial includes 80 healthy volunteers and is designed as a head to head comparison between the GRM and prednisolone, the most frequently used glucocorticoid. Observing several biomarkers, the trial will assess the influence of the investigational medicine on bone metabolism and glucose levels. Reduced bone formation leading to osteoporosis as well as increased blood glucose levels leading to an increased risk of diabetes are among the most common side-effects of glucocorticoids, which are a strong limitation for their long-term use at highly effective doses.,, The results of the stu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom